Trials / Completed
CompletedNCT01869881
Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study)
Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 151 (actual)
- Sponsor
- Yuhan Corporation · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
Phase 4 Study to evaluate the safety and effect on decreasing subjects' albuminuria who have Type 2 Diabetes by using sarpogrelate and placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anplag(Sarpogrelate) | Sarpogrelate 100mg 2 tablets, bid, 400mg/day |
| DRUG | Placebo | Placebo 100mg 2 tablets, bid, 400mg/day |
Timeline
- Start date
- 2013-02-01
- Primary completion
- 2014-11-17
- Completion
- 2015-01-28
- First posted
- 2013-06-05
- Last updated
- 2021-04-23
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01869881. Inclusion in this directory is not an endorsement.